In the early March, 2020, LifeTech Scientific organized an international academic seminar, providing an academic exchange opportunity for the American and Malaysian cardiac interventional experts. During the seminar, experts mainly discussed the clinical applications of LifeTech’s innovative interventional medical devices, which achieved a complete success.
The Serdang Hospital, Malaysia
The American expert, Dr. Daniel McLennan and his team first visited the Serdang Hospital in Malaysia, in where the Malaysian expert Dr. Koh Ghee Tiong and his team performed a Patent Ductus Arteriosus (PDA) closure procedure, a Ventricular Septal Defect (VSD) closure procedure and a PDA scaffold implantation procedure. All the devices used were LifeTech’s patented interventional congenital heart disease (CHD) products. Amongst, Dr. Koh Ghee Tiong performed the PDA scaffold implantation procedure using IBS Angel™ Iron-Based Bioresorbable Scaffold, which achieved a great success. It provides the patient with enough survival time to receive further treatment in the future.
After the procedure, Dr. Koh Ghee Tiong shared his clinical experiences with IBS Angel™ Iron-Based Bioresorbable Scaffold, including several challenging cases. Dr. Daniel McLennan excitedly expressed that IBS Angel™ could fill in the vacancy in the industry.
(Dr. Koh Ghee Tiong introduced IBS Angel™ Iron-based Bioresorbable Scaffold to the American expert, Dr. Daniel McLennan)
(A picture of American experts, Dr. Koh Ghee Tiong and his team, and LifeTech’s representatives)
The National Heart Institute of Malaysia
In the National Heart Institute of Malaysia, Dr. Mazeni Alwi and his team performed a PDA closure procedure and an ASD with Pulmonary Arterial Hypertension (ASD-PAH) closure procedure using LifeTech’s CeraFlex™ PDA Occluder and Cera™ Fenestrated ASD Occluder respectively, and both achieved great successes.
The National Heart Institute of Malaysia is the first clinical trial center of IBS Angel™ Iron-based Bioresorbable Scaffold globally. As the principal investigator of IBS Angel™ device, Dr. Mazeni Alwi introduced the clinical trial results of this novel device. The clinical data showed that the procedure immediate success rate was 100%, and the preliminary results was positive.
(Dr. Mazeni Alwi introduced the clinical trial results of IBS Angel™ to American experts)
Dr. Mazeni Alwi expressed that IBS Angel™ Iron-based Bioresorbable Scaffold has a variety of advantages, it is very suitable for infants with ductus-arteriosus-dependent complex CHD and congenital pulmonary artery diseases. Its low-profile delivery sheath makes it more applicable for newborns and infants. Moreover, as the scaffold could be fully absorbed after the implantation, the doctor could perform additional heart surgery without the need to remove the implanted scaffold. It could protect the patient’s pulmonary artery and make it easier to ligate the patient’s arterial duct, reducing the post-procedure complications.
After the academic exchange, American experts expressed that they have learned a lot from the procedures and the discussions, and they also spoke highly of LifeTech’s innovative products and advanced technology. In particular, Dr. Daniel McLennan highly praised the unique characteristics of IBS Angel™ Iron-based Bioresorbable Scaffold, he believed that the device would bring a new life to children with complex CHD who need the urgent medical treatment.